U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07208981) titled 'Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL' on Sept. 18.
Brief Summary: This is an open-label, multicenter, phase 2, non-randomized study aiming to evaluate the efficacy and safety of orelabrutinib combined with zebetuzumab and lenalidomide or bendamustine combined with rituximab in the treatment of newly diagnosed marginal zone lymphoma (MZL).
Study Start Date: Aug. 14
Study Type: INTERVENTIONAL
Condition:
Marginal Zone Lymphoma(MZL)
Intervention:
DRUG: Orelabrutinib
Induction treatment phase (a total of 6 cycles, each cycle lasting 28 days), Orelabrutinib (150 mg, d1-d28...